|Zamicastat is a dopamine β-hydroxylase (DBH) inhibitor that crosses the blood-brain barrier and causes central and peripheral effects. In addition, Zamicastat is a concentration-dependent dual P-gp and BCRP inhibitor with IC50 values of 73.8 μM and 17.0 μM, respectively.
|YHO-13177 is a potent and specific inhibitor of breast cancer resistance protein (BCRP/ABCG2).
|Fumitremorgin C (FTC) is a fungal toxin of the diketopiperazines family of compounds.
|Ko 143 is a potent and selective BCRP inhibitor.
|KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter with IC50 values of 0.59 and 1.39 μM in Pheo A and Hoechst 33342 assays, respectively.
|CCTA-1523 is a potent, selective, reversible, and orally active ABCG2 inhibitor.CCTA-1523 exhibits cytotoxicity and anticancer activity.
|Ac32Az19 is a potent, nontoxic, and highly selective BCRP inhibitor with an EC50 value of 13 nM in BCRP overexpressing HEK293/R2 cells.
|ML230 is a selective inhibitor of the ATP-binding transporter subtype ABCG2, and its inhibitory effect on ABCG2 was 36 times that of ABCB1, with EC50 values of 0.13 μM and 4.65 μM, respectively.
|(S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor that inhibits BCRP efflux transporter protein with an IC50 of 0.6 μM.
|Efflux inhibitor-1 is a pyrazolo[1,5-a]pyrimidine efflux inhibitor that also selectively targets ABCG2, with IC50s of 0.45 μM and 2.17 μM, respectively.
|ABCG2-IN-2 is a potent ABCG2 inhibitor with favorable oral pharmacokinetic profiles in mice.
|ABCG2-IN-1 is an orally active ABCG2 inhibitor with an IC50 of 0.13 μM.
|YHO-13351 free base
|YHO-13351 free base is the precursor of YHO-13177, which is a potent and specific inhibitor of BCRP.
|6,8-Diprenylnaringenin (Lonchocarpol A; Senegalensin), a hop prenylflavonoid, is a inhibitor of breast cancer resistance protein (BCRP/ABCG2). 6,8-Diprenylnaringenin inhibits ABCG2-mediated efflux of Mitoxantrone, and 3H-Methotrexate transport (IC50=0.41 μM) in HEK293 cells. 6,8-Diprenylnaringenin exhibits some estrogenicity, but its potency is less than 1% of that of 8-Prenylnaringenin.
|YHO-13351 is the precursor of YHO-13177, which is a potent and specific inhibitor of BCRP.
|ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC50 of 0.6 μM.
|Symadex is an FMS-like tyrosine kinase 3 (FLT3) and topoisomerase-II inhibitor; ABCG2 substrate; cell cycle modulator.
|CP-100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.